D E DUGGAN
Overview
Explore the profile of D E DUGGAN including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Halpin R, Ulm E, Till A, Kari P, Vyas K, Hunninghake D, et al.
Drug Metab Dispos
. 1993 Nov;
21(6):1003-11.
PMID: 7905377
Lovastatin is a prodrug lactone whose open-chain 3,5-dihydroxy acid is a potent, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis. The compound undergoes extensive and complex...
2.
Lin J, CHEN I, DUGGAN D
Drug Metab Dispos
. 1992 Jul;
20(4):473-8.
PMID: 1356720
Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate), an antiosteolytic agent, is currently under investigation in the treatment of a variety of bone disorders. Earlier studies from this laboratory have demonstrated that systemically administered drug was...
3.
Lin J, DUGGAN D, CHEN I, Ellsworth R
Drug Metab Dispos
. 1991 Sep;
19(5):926-32.
PMID: 1686238
Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is currently under investigation as an anti-osteolytic agent in the treatment of a broad range of bone disorders. This study describes the absorption and disposition of the drug...
4.
CHEN I, Hsieh J, Lin J, DUGGAN D
J Chromatogr
. 1990 Dec;
534:119-26.
PMID: 2094698
A new high-performance liquid chromatographic method coupled with solid-phase (C8) sample extraction has been developed for the simultaneous quantification of cilastatin and its major metabolite N-acetylcilastatin in rat plasma, urine...
5.
Lin J, CHEN I, Ulm E, Gehret J, DUGGAN D
Drug Metab Dispos
. 1990 Nov;
18(6):836-41.
PMID: 1981525
MK-417, a potent carbonic anhydrase inhibitor capable of reducing intraocular pressure after topical application, is currently under investigation for the treatment of glaucoma. The purposes of this study were to...
6.
Vickers S, Duncan C, Vyas K, Kari P, Arison B, Prakash S, et al.
Drug Metab Dispos
. 1990 Jul;
18(4):476-83.
PMID: 1976071
Simvastatin (SV), an analog of lovastatin, is the lactone form of 1', 2', 6', 7', 8', 8a'-hexahydro-3,5-dihydroxy-2', 6'-dimethyl-8' (2", 2"-dimethyl-1"-oxobutoxy)-1'-naphthalene-heptanoic acid (SVA) which lowers plasma cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase....
7.
Vyas K, Kari P, Prakash S, DUGGAN D
Drug Metab Dispos
. 1990 Mar;
18(2):218-22.
PMID: 1971576
Metabolism of lovastatin, a new cholesterol-lowering drug, by liver microsomes from rats and mice was investigated. Liver microsomes from rats catalyzed biotransformation of lovastatin at a rate of 3 nmol/mg...
8.
Vickers S, Duncan C, CHEN I, Rosegay A, DUGGAN D
Drug Metab Dispos
. 1990 Mar;
18(2):138-45.
PMID: 1971563
The biosynthesis of cholesterol is mainly regulated by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Because the liver is the major site of cholesterol synthesis, it is the primary target of the...
9.
10.
DUGGAN D, CHEN I, Bayne W, Halpin R, Duncan C, SCHWARTZ M, et al.
Drug Metab Dispos
. 1989 Mar;
17(2):166-73.
PMID: 2565206
Lovastatin is a pro-drug lactone whose open chain beta-hydroxy-acid (HA) is a potent inhibitor of hydroxymethylglutaryl-CoA-reductase and thus of cholesterol synthesis. Because the liver is the major site of cholesterolgenesis,...